Navigation Links
Independent Pharmacy Cooperative to Distribute Promescent, Topical Medication for Premature Ejaculation
Date:6/14/2013

Huntington Beach, CA (PRWEB) June 14, 2013

The Independent Pharmacy Cooperative (IPC) and Absorption Pharmaceuticals (AP) have signed a distribution agreement whereby IPC will make AP's topical treatment for premature ejaculation, Promescent, available to its 4,500+ member pharmacies throughout the United States.

Promescent is fast becoming first-line therapy for premature ejaculation by numerous urologists and Large Urology Groups Practice Association (LUGPA) members across the U.S., replacing off-label medications which have known side effects. Promescent is available over-the-counter by way of FDA monograph 21 CFR 348.10 and has minimal risk of systemic side effects. The effectiveness, ease-of-use, safety, and low cost per dose of the medication are key reasons for its rise in popularity among physicians.

"Urologists want their patients to have convenient and private locations for obtaining Promescent after their office visit," says Jeff Abraham, CEO of Absorption Pharmaceuticals. "The relationship with IPC now gives patients in virtually every location in the country the fast and confidential access to what has become a mainstream medication for PE."
Many independent pharmacies provide compounding services such as Trimix for erectile dysfunction. Some urologists who prescribe Trimix and other injection therapies for ED are recommending Promescent to these patients in order to achieve a better overall sexual experience.

"We have witnessed a steady growth in product demand since our first member pharmacy started carrying Promescent, " says Dean Slaugenhoup, director of contracts and purchasing at IPC . "Our mission at IPC is to provide our members cost-effective and convenient access to products that have passed a threshold of acceptance by physicians and Promescent is now clearly in this category. It was time to formalize the relationship."

IPC is now stocking Promescent at its two distribution centers and making members aware of the Promescent's availability.

About Absorption Pharmaceuticals

Absorption Pharmaceuticals, based in Huntington Beach, California, is the maker of Promescent, the world's first FDA-approved topical treatment for premature ejaculation. Promescent is now first-line PE therapy for numerous urologists and sexual medicine experts throughout the United States and Canada. Visit http://www.promescent.com.

About Independent Pharmacy Cooperative (IPC)

Over the past 30 years, IPC has evolved into the nation's largest group purchasing organization for independent pharmacies. IPC represents over 4500 pharmacy members. Located in Sun Prairie, WI and staffed by 75 employees, IPC prides itself on providing the most progressive and effective programs and services to put profit back in the independent pharmacy.

Read the full story at http://www.prweb.com/releases/2013/6/prweb10831890.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. AGA releases first independently developed ABIM-approved Practice Improvement Module in GI
2. MyTownInsurance.com Reveals How Project CAP and Insurance Agoragate will Take Away Market Share from the Captive Insurance Carriers and give it back to the Independents
3. A Void In The Independent Pharmacy Industry Leads to Independent Rx Consulting, Powered by OurHelix
4. Helping Alzheimers patients stay independent
5. Independent Care to Open New Office with Service Area Expansion
6. Funding Meals on Wheels Keeps Seniors Independent: Study
7. Study shows COPD is not independent risk factor for lung cancer
8. Omega XL Reports New Independent Study:Omega-3s Help Heal Bedsores In Critically Ill
9. Independent Research Shows That Medrio, a Leading EDC and eClinical SaaS Provider for Clinical Research, Continues to Achieve Exceptional Scores in Customer Satisfaction
10. Yumi Media Encourages Vegetarianism For Heart Health As Reported In the Independent Florida Alligator
11. Liproxenol is First Diet Pill to Earn Perfect Score from Independent Review Organization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic ... (PCN) during the summer of 2016. The program was made possible by a ... States Department of Health and Human Services Administration. The broadcast, Use Your ...
(Date:12/8/2016)... ... 08, 2016 , ... Russ DiGilio , founder and ... #QuackGivesBack campaign which supported local breast cancer organizations during National Breast Cancer Awareness ... Back initiative, and we’re very pleased with the participation in every franchisee’s ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital ... aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media ... Jr said, “CURE Media Group is honored to team up with Upstage Lung Cancer ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
(Date:12/8/2016)... ... ... STAT courier is pleased to announce that due to customer demand, as ... their presence in Dallas. One of the most exciting parts for STAT is that ... Dallas and Forth Worth market. STAT takes pride in treating their employees with integrity ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016  The global biosurgery market is ... the forecast period of 2016 to 2021. The market ... from USD 18.21 billion in 2016. The market is ... of sports related injuries and spinal problems, increasing clearance ... of effective blood loss management. In this ...
(Date:12/8/2016)... -- KEY FINDINGS North America ... in 2016 and is expected to continue in the ... large number of surgical procedures that are taking place ... the patient temperature management market.) Patient warming and cooling ... blood during surgeries, lowering the risks of neurological disorders ...
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
Breaking Medicine Technology: